Vinconate

Vinconate is an indolonaphthyridine derivative and can stimulate the muscariic acetylcholine receptor. IC50 & Target: muscariic acetylcholine receptor^[1] In Vivo: Treatment with Vinconate (50 to 200 mg/kg p.o.) significantly increases dopamine concentrations in dialysate. Daily treatment with Vinconate (25 mg/kg) for 7 days also significantly increases dopamine and serotonin concentrations in dialysate^[1]. Chronic treatment with Vinconate at a 10 mg/kg significantly ameliorats the reduction in [³H]QNB binding in the nucleus accumbens and cerebellum. Furthermore, this Vinconate treatment significantly enhances [³H]QNB binding in the frontal cortex and hippocampus compare with the vehicle-treated aged animals. Also, chronic treatment with Vinconate at the higher dose significantly elevates [³H]QNB binding in the hippocampal CA3 sector and dentate gyrus compare with the vehicle-treated aged animals. Chronic treatment with Vinconate at a dose of 10 mg/kg shows a significant reduction in [³H]HC binding only in the hippocampal CA1 sector compare with the vehicle-treated aged rats^[2].